Skip to main content
Clinical Trials/NCT01303653
NCT01303653
Unknown
Phase 1

Endoscopic Treatment of Intestinal Fistulas and Perforations

The Oregon Clinic1 site in 1 country25 target enrollmentOctober 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Gastrointestinal Fistula
Sponsor
The Oregon Clinic
Enrollment
25
Locations
1
Primary Endpoint
Number of participants with adverse events as a measure of safety and tolerability
Last Updated
15 years ago

Overview

Brief Summary

Gastrointestinal leaks or perforations are currently treated through either open or laparoscopic surgical procedures. The purpose of this research is to determine whether new endoscopic tools are safe and effective in the treatment of such conditions and can overcome the need of invasive surgical procedures.

Detailed Description

Novel endoscopic devices have the potential to overcome the need for invasive surgery for the treatment of gastrointestinal fistulas or perforations. Instead of a large abdominal incision or multiple incisions with the related postoperative morbidity endoscopic techniques will be used used which require no postoperative limitation of activities. Using novel tissue closure devices, such as a Tissue Apposition System or an endoscopic suturing system, we will evaluate the potential benefit, risks and impact on the patient's quality of life of this modified surgical technique in patients having either chronic gastrointestinal fistulas or acute perforations.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
October 2010
Last Updated
15 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Gastrointestinal fistula and perforation
  • Ability to undergo general anesthesia
  • Ability to give informed consent

Exclusion Criteria

  • Contraindicated for esophagogastroduodenoscopy (EGD)
  • Contraindicated for colonoscopy
  • Presence of esophageal stricture
  • Altered gastric anatomy
  • Intraabdominal abscess or severe inflammation

Outcomes

Primary Outcomes

Number of participants with adverse events as a measure of safety and tolerability

Time Frame: 6 months

elective endoscopy to evaluate tissue closure

Study Sites (1)

Loading locations...

Similar Trials